false
The Precision Blog
100% sourced from leading minds on the front lines of research
Recent and Featured Posts
View all articles-
Read Why Global Oncology Evidence May Not Support U.S. Regulatory Approval
-
Read Receptor Occupancy in the Era of Multispecific Therapeutics Receptor Occupancy in the Era of Multispecific Therapeutics
Read Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors
Read
-
-
Read: Why Global Oncology Evidence May Not Support U.S. Regulatory Approval 
Why Global Oncology Evidence May Not Support U.S. Regulatory Approval
has not third author: true, (SizeLimitingPyMap: {main={hs_id=167363064857, hs_child_table_id=0, hs_updated_at=1719905898183, hs_published_at=1785476963368, description=Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors., avatar=Image{width=553,height=580,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Harpreet-Singh2.png',altText='Harpreet-Singh2',fileId=171747124346}, linkedin=https://www.linkedin.com/in/harpreetsinghmd/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Singh, MD, hs_initial_published_at=1715692570942, hs_created_by_user_id=2737751, hs_created_at=1715692477118, hs_is_edited=false, hs_deleted_at=0, name=Harpreet, job=Chief Medical Officer, slug=harpreet-singh, hs_updated_by_user_id=65160865}, second={}, third={}}) -
-
Read: Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors 
Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors
has not third author: true, (SizeLimitingPyMap: {main={hs_id=164713188870, hs_child_table_id=0, hs_updated_at=1754641424769, hs_published_at=1785476963368, description=Deana Demjen is Director of the Precision Site Network, bringing nearly 20 years of clinical research to the role. Most of her previous experience has been in feasibility and site-identification. She has been covering a wide range of therapeutic areas, but her main focus are rare diseases where she is an acting subject matter expert. She is responsible for relationships with PSN sites as well as the maintenance and expansion of the network., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Deana-Demjen-1.png',altText='Deana-Demjen-1',fileId=194123711869}, lastname=Demjen, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713363112834, hs_is_edited=false, hs_deleted_at=0, name=Deana, job=Director of PSN, slug=deana-demjen, hs_updated_by_user_id=65160865}, second={}, third={}}) -
-
Read: Why APAC Is Becoming a Design Decision 
Why APAC Is Becoming a Design Decision
has third author: false, (SizeLimitingPyMap: {main={hs_id=199521241215, hs_child_table_id=0, hs_updated_at=1774887081250, hs_published_at=1785476963368, description=An industry veteran with nearly three decades of experience in the clinical research industry and deep expertise in clinical operations and strategic leadership across both pharmaceutical and CRO environments. Held pivotal roles as Head of Clinical Operations for Greater China at Boehringer Ingelheim, leading trials in oncology, respiratory, stroke, and cardio-metabolic diseases and CEO of George Clinical, a global CRO with strong scientific capabilities in renal and oncology therapeutic areas. At Precision for Medicine, a leader for business strategy across the Asia Pacific region. Focused on driving regional growth, building strategic partnerships, and supporting excellence in portfolio delivery and client satisfaction. An acknowledged driver of precision-driven solutions that improve patient outcomes., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/James%20Cheong.png',altText='James Cheong',fileId=199519079710}, linkedin=https://www.linkedin.com/in/james-cheong-36a543a/, lastname=Cheong, hs_initial_published_at=1762885727645, hs_created_by_user_id=78347666, hs_created_at=1762885637470, hs_is_edited=false, hs_deleted_at=0, name=James, job=Senior Vice President, Asia Pacific, Clinical Solutions, slug=james-cheong, hs_updated_by_user_id=65160865}, second={hs_id=199519203221, hs_child_table_id=0, hs_updated_at=1770145994248, hs_published_at=1785476963368, description=Highly accomplished global clinical operations executive with nearly three decades of experience providing strategic leadership, regional expansion, and operational excellence across Asia Pacific. Brings deep expertise across clinical development, project and portfolio operations, biometrics, regulatory affairs, safety and pharmacovigilance, quality management, and financial governance. Proven builder and scaler of high‑performing teams and start‑up operations in both regional and global environments. Recognized industry leader who actively contributes to advancing clinical research standards through advisory and governance roles across Asia., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Jing%20Ping%20Yeo.png',altText='Jing Ping Yeo',fileId=199530854290}, linkedin=https://www.linkedin.com/in/jing-ping-yeo/, lastname=Yeo, PhD , hs_initial_published_at=1762893310168, hs_created_by_user_id=78347666, hs_created_at=1762893091367, hs_is_edited=false, hs_deleted_at=0, name=Jing Ping, job=Vice President, Clinical Operations, Head of Asia Pacific, slug=JingPing-Yeo, hs_updated_by_user_id=65160865}, third={hs_id=199528025104, hs_child_table_id=0, hs_updated_at=1774885968488, hs_published_at=1785476963368, description=With 20+ years of experience in the clinical trial industry, he has led project management, clinical operations, and business development teams. Prior to joining Precision, he served as the General Manager of Emerald (formerly George Clinical) China, and held project management and business development leadership roles at ICON, WuXi CDS, IQVIA, and KUNTUO. He has successfully led teams to complete more than 120 Phase I–IV clinical trials, many of which were MRCT studies across Asia‑Pacific, Australia, and the United States. He holds a Master’s degree in Urology from Peking University First Hospital., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Zhenfei%20Yin.png',altText='Zhenfei Yin',fileId=199530854553}, lastname=Yin, hs_initial_published_at=1762893310168, hs_created_by_user_id=78347666, hs_created_at=1762893190542, hs_is_edited=false, hs_deleted_at=0, name=Zhenfei, job=China Country Head, Senior Director, Project Management, slug=Zhenfei Yin, hs_updated_by_user_id=65160865}}) -
-
-
-
Read: Receptor Occupancy in the Era of Multispecific Therapeutics 
Receptor Occupancy in the Era of Multispecific Therapeutics
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1785476963368, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=65160865}, second={hs_id=218178874459, hs_child_table_id=0, hs_updated_at=1785241362455, hs_published_at=1785476963368, description=Jenny Zilberberg has more than 20 years of combined experience across academia and biotechnology, with expertise in translational immunology, cancer immunotherapy, and biomarker strategy. Most recently, she served as Head of Research at Imvax, where she led preclinical development and biomarker activities for the company’s immunotherapy platform and lead glioblastoma program. At Precision, Jenny partners with sponsors to design and implement biomarker and bioanalytical solutions that support clinical development across oncology and autoimmune diseases., avatar=Image{width=480,height=480,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/JennyZilberberg.jpeg',altText='JennyZilberberg',fileId=218182303073}, lastname=Zilberberg, hs_initial_published_at=1785241367324, hs_created_by_user_id=65712240, hs_created_at=1785241302354, hs_is_edited=false, hs_deleted_at=0, name=Jenny, job=Vice President, Scientific Strategy, slug=Jenny-zilberberg, hs_updated_by_user_id=65160865}, third={}}) -
-
Read: Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research 
Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research
has not third author: true, (SizeLimitingPyMap: {main={hs_id=199448088864, hs_child_table_id=0, hs_updated_at=1762810484868, hs_published_at=1785476963368, avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Kaylee%20Mueller.png',altText='Kaylee Mueller',fileId=199456336149}, lastname=Mueller, hs_initial_published_at=1762810487482, hs_created_by_user_id=26433386, hs_created_at=1762810467146, hs_is_edited=false, hs_deleted_at=0, name=Kaylee, slug=kaylee-mueller, hs_updated_by_user_id=65160865}, second={}, third={}}) -
-
Read: Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data 
Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data
has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778886, hs_child_table_id=0, hs_updated_at=1763657611624, hs_published_at=1785476963368, description=Robert Snyder, PhD, is a seasoned expert with a 20-year track record in genomics, specializing in in vitro diagnostic assay development and bioinformatics. Committed to advancing medical science, he is proficient in regulatory V&V study designs and understands the nuances of orthogonal methods. A collaborative partner in biomedical development, Dr. Snyder champions the critical transition of biospecimens from benchtop to bedside., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Robert%20Snyder.webp',altText='Robert Snyder',fileId=165892444501}, linkedin=https://www.linkedin.com/in/robert-snyder-ph-d-9b67b035, hs_name=, hs_path=, lastname=Snyder, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745117, hs_is_edited=false, hs_deleted_at=0, name=Robert, job=, slug=robert-snyder, email=, hs_updated_by_user_id=65160865}, second={}, third={}}) -
-
All articles
-
Read: How To Calculate Viral Vector Yields - A Critical Component Of The 'Make vs Buy' Analysis 
How To Calculate Viral Vector Yields - A Critical Component Of The 'Make vs Buy' Analysis
has not third author: true, (SizeLimitingPyMap: {main={hs_id=164426546553, hs_child_table_id=0, hs_updated_at=1716454239819, hs_published_at=1785476963368, description=Life sciences leader who helped pioneer the industrialization of biologics and advanced therapies. Deep expertise in small and large molecules, honed through work with a range of life science organizations, from start-ups and academic centers to financial institutions and CMOs/CROs. Spearheaded significant global turnkey facility builds, automation, validation, engineering, and serialization track and trace, deploying billions in capital across the life sciences sector. Led the creation of the Advanced Therapy Manufacturing Playbook which has helped develop the world’s largest advanced therapy manufacturing footprint. Actively serves on multiple boards including academic, philanthropic, biotech, and financial investment institutions., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Tony%20Khoury.webp',altText='Tony Khoury',fileId=165893018152}, linkedin=https://www.linkedin.com/in/tony-khoury-7470755/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Khoury, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713169549303, hs_is_edited=false, hs_deleted_at=0, name=Tony, job=Executive Vice President, Manufacturing Solutions, slug=tony-khoury, hs_updated_by_user_id=65160865}, second={hs_id=165403836680, hs_child_table_id=0, hs_updated_at=1716326428569, hs_published_at=1785476963368, avatar=Image{width=572,height=680,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Christian-Hermanas.png',altText='Christian-Hermanas',fileId=167581705333}, linkedin=https://www.linkedin.com/in/christianhermanas/, lastname=Hermanas, hs_initial_published_at=1713967130374, hs_created_by_user_id=62155952, hs_created_at=1713965852214, hs_is_edited=false, hs_deleted_at=0, name=Christian, job=Sr. Manager, Precision for Medicine Manufacturing Solutions, slug=christian-hermanas, hs_updated_by_user_id=65160865}, third={}}) -
-
Read: Dos And Don'ts Of Virtual Factory Acceptance Testing In Life Sciences 
Dos And Don'ts Of Virtual Factory Acceptance Testing In Life Sciences
has third author: false, (SizeLimitingPyMap: {main={hs_id=164426546553, hs_child_table_id=0, hs_updated_at=1716454239819, hs_published_at=1785476963368, description=Life sciences leader who helped pioneer the industrialization of biologics and advanced therapies. Deep expertise in small and large molecules, honed through work with a range of life science organizations, from start-ups and academic centers to financial institutions and CMOs/CROs. Spearheaded significant global turnkey facility builds, automation, validation, engineering, and serialization track and trace, deploying billions in capital across the life sciences sector. Led the creation of the Advanced Therapy Manufacturing Playbook which has helped develop the world’s largest advanced therapy manufacturing footprint. Actively serves on multiple boards including academic, philanthropic, biotech, and financial investment institutions., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Tony%20Khoury.webp',altText='Tony Khoury',fileId=165893018152}, linkedin=https://www.linkedin.com/in/tony-khoury-7470755/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Khoury, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713169549303, hs_is_edited=false, hs_deleted_at=0, name=Tony, job=Executive Vice President, Manufacturing Solutions, slug=tony-khoury, hs_updated_by_user_id=65160865}, second={hs_id=164426546589, hs_child_table_id=0, hs_updated_at=1716326136263, hs_published_at=1785476963368, description=Respected technical and quality advisor to both start-ups and established pharmaceutical companies for CMO/CDMO operational readiness capabilities. Subject matter expert in designing, implementing, and maintaining cGMP facilities. Has led multiple capital projects for partners in the advanced therapies and biologics spaces., avatar=Image{width=720,height=812,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Daniel-Foody.png',altText='Daniel-Foody',fileId=167370294648}, linkedin=https://www.linkedin.com/in/danny-foody/, team=[{id=163080551774, name='Manufacturing Solutions Leadership'}], lastname=Foody, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713170108117, hs_is_edited=false, hs_deleted_at=0, name=Danny, job=Director, slug=danny-foody, hs_updated_by_user_id=65160865}, third={hs_id=164426546583, hs_child_table_id=0, hs_updated_at=1734630588121, hs_published_at=1785476963368, description=Trusted life sciences authority leading integrated teams in biologics, blood therapies and next generation medicines. Spearheads task forces focused on technical strategy and execution related to compliant pre-clinical, clinical, and commercial manufacturing. Directs agile teams across a range of functional areas spanning project management, facilities, infrastructure, process equipment, manufacturing operations, and quality projects., avatar=Image{width=668,height=710,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Phillip-Massey1.png',altText='Phillip-Massey1',fileId=167374597237}, linkedin=https://www.linkedin.com/in/phillip-massey-22baa257/, team=[{id=163080551774, name='Manufacturing Solutions Leadership'}], lastname=Massey, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713169955307, hs_is_edited=false, hs_deleted_at=0, name=Phil, job=Vice President, slug=phil-massey, hs_updated_by_user_id=65160865}}) -
-
Read: Best Practices for CDMO Evaluation, Selection, and Management 
Best Practices for CDMO Evaluation, Selection, and Management
has not third author: true, (SizeLimitingPyMap: {main={hs_id=164426546553, hs_child_table_id=0, hs_updated_at=1716454239819, hs_published_at=1785476963368, description=Life sciences leader who helped pioneer the industrialization of biologics and advanced therapies. Deep expertise in small and large molecules, honed through work with a range of life science organizations, from start-ups and academic centers to financial institutions and CMOs/CROs. Spearheaded significant global turnkey facility builds, automation, validation, engineering, and serialization track and trace, deploying billions in capital across the life sciences sector. Led the creation of the Advanced Therapy Manufacturing Playbook which has helped develop the world’s largest advanced therapy manufacturing footprint. Actively serves on multiple boards including academic, philanthropic, biotech, and financial investment institutions., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Tony%20Khoury.webp',altText='Tony Khoury',fileId=165893018152}, linkedin=https://www.linkedin.com/in/tony-khoury-7470755/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Khoury, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713169549303, hs_is_edited=false, hs_deleted_at=0, name=Tony, job=Executive Vice President, Manufacturing Solutions, slug=tony-khoury, hs_updated_by_user_id=65160865}, second={}, third={}}) -
You've reach the end
